InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - ETF Exposure

- Current share price for ATX : $0.079

Amplia Therapeutics Limited (ATX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a role in chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

ATX General Information +

ASX Code ATX
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 40
ATX Share Price $0.079
Day High $0.079
Day Low $0.076
Last Close $0.079
ATX Share Price Movement - ( No change )
Prices as at 16:40, 20 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to ATX

Amplia Therapeutics Limited (ATX) is held across 1 ETF spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when ATX moves, funds like DACE that hold it can move with it.

For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to ATX , while the average exposure across all 1 ETF that hold it is around 0% .

Top ETF holdings

Last updated: ETF data and holdings as at 20 November 2026

Own ATX directly or through an ETF?

How does holding Amplia Therapeutics Limited (ATX) shares directly compare to ETFs that include it?

ATX Direct
DACE
ASX
Holdings 1 company 510 holdings
ATX Weight 100% 0%
Diversification Single Stock Broad
Annual Cost Brokerage only 0.28% p.a.
Approx. Yield 0% 3.31%
Star Ratings - starstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ATX's direct yield. Annual cost uses each ETF's MER.

ATX Exposure on $10,000 investment

How a $10,000 investment in Amplia Therapeutics Limited (ATX) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Amplia Therapeutics Limited (ATX) Direct share $0.079 -12.22% -$1,222 $8,778
Dimensional Australian Core Equity (Managed Fund) (DACE) Equity - Australia Strategy $17.820 -6.36% -$636 $9,364

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Amplia Therapeutics Limited (ATX) ETFs

1 ETF hold Amplia Therapeutics Limited (ATX).

ETF ATX Weight MER Yield
Dimensional Australian Core Equity (Managed Fund) (DACE) 0% 0.28% 3.31%

Amplia Therapeutics Limited (ATX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Amplia Therapeutics Limited (ATX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Amplia Therapeutics Limited (ATX) price-sensitive announcements

ATX - Ethics Approval for Amplia's ACCENT-Mini Trial
Amplia Therapeutics Limited announced that it has received ethics approval for its ACCENT-
Amplia Therapeutics Limited (ATX)
19 Nov 2026 | 8:27 AM
ATX - Quarterly Activities/Appendix 4C Cash Flow Report
Amplia Therapeutics Limited (ASX: ATX) reported continued progress for the quarter ended 3
Amplia Therapeutics Limited (ATX)
28 Oct 2026 | 8:22 AM
ATX - Amplia Receives R&D Tax Rebate Totalling $4.78 Million
Amplia Therapeutics Limited announced that it received A$4,778,235.52 from the Australian
Amplia Therapeutics Limited (ATX)
22 Oct 2026 | 1:45 PM
ATX - Response to ASX Price Query
Amplia Therapeutics Limited released a response to an ASX price query on 16 October 2026 a
Amplia Therapeutics Limited (ATX)
16 Oct 2026 | 2:19 PM

Amplia Therapeutics Limited (ATX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Amplia Therapeutics Limited (ATX)
ORDINARY FULLY PAID
Health Care $41 Ethics Approval for Amplia's ACCENT-Mini Trial 19 Nov 2026 8:27AM $0.081 $0.079 fallen by 2.47%
Amplia Therapeutics Limited (ATX)
ORDINARY FULLY PAID
Health Care $41 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2026 8:22AM $0.079 $0.079 fallen by 0%
Amplia Therapeutics Limited (ATX)
ORDINARY FULLY PAID
Health Care $41 Amplia Receives R&D Tax Rebate Totalling $4.78 Million 22 Oct 2026 1:45PM $0.077 $0.079 risen by 2.60%
Amplia Therapeutics Limited (ATX)
ORDINARY FULLY PAID
Health Care $41 Amplia Therapeutics Provides Clinical Trial Updates 22 Oct 2026 8:17AM $0.081 $0.079 fallen by 2.47%
Amplia Therapeutics Limited (ATX)
ORDINARY FULLY PAID
Health Care $41 Response to ASX Price Query 16 Oct 2026 2:19PM $0.078 $0.079 risen by 1.28%
Amplia Therapeutics Limited (ATX)
ORDINARY FULLY PAID
Health Care $41 Amplia Presents at CG Drug and Device Conference 2026 13 Oct 2026 8:18AM $0.110 $0.079 fallen by 28.18%

ATX Financial Summary

Year to Mar NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$7.71 -$1.60 -23.40% 0.00 0.00 0.00% 0.0%
2025A -$6.57 -$2.10 -3.20% 0.00 0.00 0.00% 0.0%
2024A -$4.50 -$2.20 -28.00% 0.00 0.00 0.00% 0.0%

ATX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Amplia Therapeutics Limited (ATX) $41M -0.2336 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL Limited (CSL) $95,905M 0.7309 -0.4349 0.0602 12.3811 21.9110 20.6672 2.13% 2.15% 2.22%
Mesoblast Limited (MSB) $2,219M -0.4501 0.0000 0.0000 0.0000 0.0000 775.0000 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,605M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,499M -1.3893 0.0000 -0.5234 0.0000 154.4393 324.0196 0.00% 0.00% 0.00%

ATX Directors

Name Position Start Date
Dr Christopher John Burns Chief Executive Officer, Managing Director 4 May 2018
Mr Andrew John Cooke Company Secretary 1 Jan 0001
Dr Robert Peach Non-Executive Director 2 Sep 2015
Dr Warwick Bonner Tong Non-Executive Director 4 May 2018
Mr Brett Anthony Carter Non-Executive Director 6 Jul 2026
Ms Jane Catherine Bell Non-Executive Director, Non-Executive Chairman 12 Apr 2021

Amplia Therapeutics Limited (ATX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
1 Sep 2025 BELL, Jane Issued Indirect Shares 130,435 $0.230 $30,000.050
1 Sep 2025 TONG, Warwick Issued Indirect Shares 152,174 $0.230 $35,000.020
1 Sep 2025 BURNS, Christopher Issued Direct Shares 86,957 $0.230 $20,000.110

See all changes in directors' interest & trades for Amplia Therapeutics Limited (ATX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ATX Management

Name Position
Hamish George Chief Financial Officer
Jason Lickliter Chief Medical Officer

ATX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Amplia Therapeutics Limited (ATX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
45,313,932 (9.31%) Platinum Investment Management Limited
36,144,321 (7.43%) Acorn Capital Limited

ATX Calendar of Events

Date Event
28 May 2027 Report (Annual)
28 May 2027 Report (Prelim)
26 November 2026 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.